Comparison of biosimilar Tigerase and Pulmozyme in long-term symptomatic therapy of patients with cystic fibrosis and severe pulmonary impairment (subgroup analysis of a Phase III randomized open-label clinical trial (NCT04468100))

BACKGROUND: Patients with cystic fibrosis (CF) need costly medical care and adequate therapy with expensive medicinal products. Tigerase(®) is the first biosimilar of dornase alfa, developed by the lead Russian biotechnology company GENERIUM. The aim of the manuscript to present post hoc sub-analysi...

Descripción completa

Detalles Bibliográficos
Autores principales: Amelina, Elena L., Krasovsky, Stanislav A., Akhtyamova-Givirovskaya, Nina E., Kashirskaya, Nataliya Yu., Abdulganieva, Diana I., Asherova, Irina K., Zilber, Ilya E., Kozyreva, Liliya S., Kudelya, Lubov M., Ponomareva, Natalya D., Revel-Muroz, Nataliya P., Reutskaya, Elena M., Stepanenko, Tatiana A., Seitova, Gulnara N., Ukhanova, Olga P., Magnitskaya, Olga V., Kudlay, Dmitry A., Markova, Oksana A., Gapchenko, Elena V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8699637/
https://www.ncbi.nlm.nih.gov/pubmed/34941914
http://dx.doi.org/10.1371/journal.pone.0261410

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8699637/
https://www.ncbi.nlm.nih.gov/pubmed/34941914
http://dx.doi.org/10.1371/journal.pone.0261410

Ejemplares similares